| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20df82048f5ae2f63dc23b0eea7a47a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95a22228273850f2f751eb644cc32a91 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6081 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y401-01028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y114-16002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2020-03-10^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_badf86f6960484eb32cca74d8eaba662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a91a0d0c28664d78ca59aa8205e7d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34bd98221c3fcfd5810fdcf12afc6e9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52839ef0b70175dab55708e9ae947efc |
| publicationDate |
2022-06-09^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022175962-A1 |
| titleOfInvention |
Gene therapy compositions and methods for treating parkinson's disease |
| abstract |
A method of improving motor function and reducing dyskinesia in a subject suffering from a neurodegenerative disease or a disease where endogenous dopamine levels are reduced in the subject comprising administering an effective amount of a viral vector comprising a nucleic acid construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1), (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC), or any combination thereof to the subject. |
| priorityDate |
2019-03-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |